Legal Cannabis Market is an Opportunity

Wednesday, February 22, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, February 22, 2017 /PRNewswire/ --

A research report by Arcview Market Research focused on cannabis sales

in North America and the continuously changing landscape of the legal market reveals that regulated cannabis sales totaled $6.9 billion in 2016 in the North America,
a 30% increase from 2015. According to the research sales are projected to increase to $21.6 billion by the year 2021 representing a 26 percent compound annual growth rate. The use of cannabis in the United States and Canada is gradually becoming more mainstream thanks to successful legalization campaigns in several states and customers who are better educated about the products are becoming more open for policy changes. Naturally Splendid Enterprises Ltd. (OTC: NSPDF) (TSX-V: NSP.V), Eco Science Solutions Inc. (OTC: ESSI), Lexaria Bioscience Corporation (OTC: LXRP), CV Sciences Inc. (OTC: CVSI), Cannabis Sativa Inc. (OTCQB: CBDS)

Another factor that affects the cannabis market is digitization. According to Research and Markets, "The cannabis market is set to undergo major changes with the ongoing digitization trend in business processes and its impact on corporate business models. Many vendors are using the internet to reach a large number of targeted audience through online and mobile advertisements."

Naturally Splendid Enterprises Ltd. (OTCQB: NSPDF) (TSX-V: NSP.V) just announced this morning that the company, "will be presenting an expanded line of CBD formulated products at FOODEX JAPAN 2017 from March 7-10 in addition to the line of CBD formulated capsules announced in a previous news release.

Naturally Splendid is pleased to announce its wholly owned U.S. subsidiary has signed an exclusive sales agreement with a leading CBD manufacturer for a complete suite of CBD formulated products. The products include; three (3) nanomist oral sprays for pain discomfort, brain cognisance and anti-anxiety; three (3) nano-formulated CBD topicals for localized pain and stress relief; two (2) CBD 2 oz shots, one for energy, one for sleep; and a CBD / herbal blend formulated capsule for pain relief.

The exclusive sales agreement is for a term of three (3) years, provided Naturally Splendid reaches certain cumulative sales volumes, and covers Japan as well as additional countries. The additional countries will be announced on a timely basis as the strategic marketing plan is implemented to cover these multiple territories. In total, Naturally Splendid will be launching nine (9) CBD formulated SKUs under this agreement and four (4) CBD formulated SKU's including one energy gum product from a previous announced exclusive sales agreement. This represents a total of fourteen (14) new SKUs to be launched at FOODEX JAPAN.

Naturally Splendid President Mr. J. Craig Goodwin states, "We are most pleased to be able to complete these two exclusive sales agreements, which combined represent a comprehensive CBD formulated line of products. Japan will be our initial target. However, our exclusive sales agreements cover multiple countries and we will be systematically launching this CBD product line in countries that have already been identified. We will continue to source additional CBD formulated products to augment the CBD products which we now offer."

Naturally Splendid CEO Dave Eto States, "This now provides our new product line NATERAŽ CBD with versatility in marketing and also allows us to be nimble when approaching new customers. We see this as a positive step towards internationally branding our entire NATERAŽ division, which includes; NATERAŽ INGREDIENTS, NATERAŽ HEMPFOODS, NATERAŽ SKINCARE and NATERAŽ CBD. I look forward to providing updates on our integration of this branding strategy and to provide updates from our trip to FOODEX JAPAN."

FOODEX JAPAN is the largest annual food and beverage tradeshow in Asia and has been a highly successful trade event since its debut in 1976 serving Japan's $585 billion food market and additional significant Asian markets. Over 76,500 professional visitors attended FOODEX 2016, including over 9,000 from Korea, Taiwan, China, Thailand, and Hong Kong. All CBD products will be sold only in jurisdictions that legally permit the purchase and sale of such products."

Technology-focused Company targeting the wellness and alternative medicine industry, Eco Science Solutions Inc. (OTCQB: ESSI) develops technical solutions, including enterprise software solutions, entertaining and useful content generation for mass distribution, and consumer applications for daily use. The company's medical cannabis information application, Herbo helps consumers find products and services that support the intake of alternative medicines for a naturopathic way of living. Recently, the company agreed to become a Presenting Partner Sponsor for Kaya Fest's inaugural event.

Lexaria Bioscience Corporation (OTCQB: LXRP) is a food biosciences company with a proprietary technology for improved delivery of bioactive compounds. The Company's lipophilic enhancement technology has been shown to enhance the bioavailability of orally ingested cannabinoids, while also improving taste. This technology promotes healthy ingestion methods, lower overall dosing and higher effectiveness in active molecule delivery. The Company's technology is patent-protected for cannabidiol and all other non-psychoactive cannabinoids, and patent-pending for Tetrahydrocannabinol, other psychoactive cannabinoids, non-steroidal anti-inflammatory drugs, nicotine and other molecules.

CV Sciences Inc. (OTCQB: CVSI) operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and, a consumer product division in manufacturing, marketing and selling plant-based CBD products to a range of market sectors. CV Sciences' Pharmaceutical Division is developing synthetically?formulated cannabidiol?based medicine, pursuing the approval of the U.S. Food and Drug Administration (FDA) for drugs with specific indications utilizing cannabidiol as the active pharmaceutical ingredient. CV Sciences has achieved promising preclinical results in the development of cannabinoid medicines for treatment of a range of medical conditions.

Cannabis Sativa Inc. (OTCQB: CBDS) develops and promotes natural cannabis products. The Company is engaged in the research, development and licensing of natural cannabis products, including cannabis formulas, edibles, topicals, strains, recipes and delivery systems. The Company plans to develop, produce and market products through joint ventures with companies licensed under state regulations applicable to cannabis businesses. It holds the license for a medicinal cannabis strain called NZT, a cannabis lozenge delivery methodology, and a cannabis trauma cream formula. The Company is also developing a third strain of cannabis plant named CT22. The Company also conducts its operations through its subsidiary, Wild Earth Naturals, Inc. Wild Earth is an herbal skin care products formulation and marketing company that plans to target the natural healthcare products market in the United States and abroad. It offers Go Deep, Go Deep EXTRA, Face Garden, Body Garden and Lip Garden.

Please SIGN UP NOW at To Receive Alerts on Trending Financial News from all these companies. "The Latest Buzz in Financial News"

Subscribe Now! Watch us report from NYSE

Follow us on Twitter for real time Financial News Updates:

Follow and talk to us on Instagram:

Facebook Like Us to receive live feeds:

About, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, creates 100% unique original content. also provides financial news PR branding, marketing and advertising for third parties for disseminating news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on (the "Site") is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content),, a financial news media and marketing firm enters into service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. has not been compensated directly by any of the companies mentioned here in this editorial. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. receives fees for producing and presenting high quality and sophisticated content on along with other financial news PR media services. does not offer any personal opinions as we purely incorporate public market research along with financial and corporate news. only regurgitates financial or corporate news through our unique financial newswire and media platform. has been compensated a total of seven thousand dollars for financial news dissemination and PR services by a third party non affiliate for naturally splendid enterprises ltd. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. will always disclose any compensation in securities or cash payments for financial news PR advertising. does not undertake to update any of the information on the Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security., members and affiliates are not responsible for any gains or losses that result from the opinions expressed on the Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. By accessing this website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use. Please visit:

For further information: Media Contact: , +1-877-601-1879



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store